Bacterin Beats Wall Street’s Expectations for Q2

Bacterin International Holdings, Inc., the Belgrade, Montana-based biologics and allograft company, surprised its analysts by pre-reporting and exceptional sales report for the June quarter. According to management, Bacterin will report sales of around $10 million for the three months ended June 30, up 12-15% from last year.

To put that in perspective, Bacterin had reported essentially zero growth in 2013, 6.8% sales growth in 2014 and now this year appears to be on track to post up 12-15%.

That’s an outstanding turnaround and is no doubt due to both a reorganization put in place by CEO Dan Goldberger and President Robert Di Silvio and a series of new products. The most recent new product introduction was ArthroFuse.

ArthroFuse is an allograft implant specifically designed for the treatment of hammertoe deformities.

According to a June 3 press release, hammertoe deformity affects the proximal interphalangeal joint of the lesser metatarsals and often resulting in debilitating joint pain and disability. There are approximately 550, 000 surgical hammertoe procedures are performed each year in the United States. But an astonishing 60 million affected adults go undiagnosed.

What is most interesting about ArthroFuse is that it eliminates the need for externally communicating pins or permanent implants. ArthroFuse remodels over time into the patient’s own bone.

So, better organization and a growing stream of innovative products and…sales are jumping.

In fact, the sequential sales growth is a very impressive 5-7% when compared to $9.5 million for the first quarter of 2015.

Bacterin supplies allograft and biologic products for a wide variety of orthopedic applications including enhancing fusion in spine surgery, relief of back pain, promotion of bone growth in foot and ankle surgery, promotion of cranial healing following neurosurgery and subchondral repair in knee and other joint surgeries.